Sec Form 4 Filing - Zhai Yifan @ ASCENTAGE PHARMA GROUP INTERNATIONAL - 2026-05-20

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Zhai Yifan 2. Issuer Name and Ticker or Trading Symbol ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Medical Officer (Last) (First) (Middle) C/O ASCENTAGE PHARMA GROUP INC., 700 KING FARM BLVD., SUITE 510 3. Date of Earliest Transaction (MM/DD/YY) 05/20/2026 (Street) ROCKVILLE, MD20850 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares 05/21/2026 M 92,746 A $ 0 405,280 D Ordinary Shares 22,054,131 I See Footnote (1) ( 1 ) Ordinary Shares 05/21/2026 M 95,575 A $ 0 1,193,569 I See Footnote (2) ( 2 ) Ordinary Shares 14,089,111 I See Footnote (3) ( 3 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted stock units ( 4 ) $ 0 05/20/2026 A 103,365 ( 4 ) ( 4 ) Ordinary Shares 103,365 $ 0 103,365 D Restricted stock units ( 5 ) $ 0 05/20/2026 A 214,999 ( 5 ) ( 5 ) Ordinary Shares 214,999 $ 0 214,999 D Options ( 6 ) $ 6.58 05/20/2026 A 214,988 ( 6 ) ( 6 ) Ordinary Shares 214,988 $ 0 214,988 D Options ( 7 ) $ 8.12 05/20/2026 A 103,364 ( 7 ) ( 7 ) Ordinary Shares 103,364 $ 0 103,364 D Restricted stock units ( 8 ) $ 0 05/20/2026 A 92,746 05/21/2026 ( 8 ) Ordinary Shares 92,746 $ 0 92,746 D Restricted stock units ( 9 ) $ 0 05/21/2026 M 92,746 ( 9 ) ( 9 ) Ordinary Shares 92,746 $ 0 0 D Restricted stock units ( 8 ) $ 0 05/20/2026 A 95,575 05/21/2026 ( 8 ) Ordinary Shares 95,575 $ 0 95,575 I By Spouse Restricted stock units ( 10 ) $ 0 05/21/2026 M 95,575 ( 10 ) ( 10 ) Ordinary Shares 95,575 $ 0 0 I By Spouse Restricted stock units ( 5 ) $ 0 05/20/2026 A 298,195 ( 5 ) ( 5 ) Ordinary Shares 298,195 $ 0 298,195 I By Spouse Options ( 6 ) $ 6.58 05/20/2026 A 298,194 ( 6 ) ( 6 ) Ordinary Shares 298,194 $ 0 298,194 I By Spouse

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Zhai Yifan C/O ASCENTAGE PHARMA GROUP INC. 700 KING FARM BLVD., SUITE 510 ROCKVILLE, MD20850 Chief Medical Officer Signatures /S/Thomas J. Knapp, Attorney-in-Fact 05/22/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Shares held by Dajun Yang Dynasty Trust, of which the Reporting Person's spouse is the investment advisor. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. ( 2 )Shares held by Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. ( 3 )Shares held by HealthQuest Pharma Limited, an entity controlled by the Reporting Person. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. ( 4 )Each restricted stock unit (the "RSUs") represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and have no expiration date. ( 5 )The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date. ( 6 )The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant. ( 7 )The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and expire ten years from the date of grant. ( 8 )The RSUs vested on 05/21/2026 and had no expiration date. ( 9 )Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person on 05/20/2026. ( 10 )Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person's spouse on 05/20/2026.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.